Literature DB >> 16688341

Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands.

Elisabeth Garanger1, Didier Boturyn, Jean-Luc Coll, Marie-Christine Favrot, Pascal Dumy.   

Abstract

We study herein the multivalency effect of a cluster of alphaVbeta3-ligands held on a cyclodecapeptide template. An array of RAFT(c[-RGDfK-])n derivatives containing from one to sixteen clustered RGD motifs were synthesized and comparatively assayed in vitro on alphaVbeta3-expressing cells. Efficient inhibition of the alphaVbeta3-specific 23C6 monoclonal antibody fixation was observed with ligands displaying three and four copies of the cyclo[-RGDfK-] peptide.

Mesh:

Substances:

Year:  2006        PMID: 16688341     DOI: 10.1039/b517706e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  21 in total

1.  Application of click-click chemistry to the synthesis of new multivalent RGD conjugates.

Authors:  Mathieu Galibert; Lucie Sancey; Olivier Renaudet; Jean-Luc Coll; Pascal Dumy; Didier Boturyn
Journal:  Org Biomol Chem       Date:  2010-09-09       Impact factor: 3.876

2.  In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.

Authors:  Lucie Sancey; Valérie Ardisson; Laurent M Riou; Mitra Ahmadi; Danièle Marti-Batlle; Didier Boturyn; Pascal Dumy; Daniel Fagret; Catherine Ghezzi; Jean-Philippe Vuillez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-04       Impact factor: 9.236

3.  Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Biotechnol Bioeng       Date:  2011-07-19       Impact factor: 4.530

Review 4.  Fluorescent molecular imaging: technical progress and current preclinical and clinical applications in urogynecologic diseases.

Authors:  V M Alexander; P L Choyke; H Kobayashi
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

5.  Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.

Authors:  Anastassia Karageorgis; Michaël Claron; Romain Jugé; Caroline Aspord; Fabien Thoreau; Claire Leloup; Jérôme Kucharczak; Joël Plumas; Maxime Henry; Amandine Hurbin; Pascal Verdié; Jean Martinez; Gilles Subra; Pascal Dumy; Didier Boturyn; Abdel Aouacheria; Jean-Luc Coll
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

6.  Integrin adjunct therapy for melanoma.

Authors:  Kumari L Andarawewa; Konstadinos Moissoglu; Chang Sup Lee; Yuta Ando; Min Yu; Prianka Debnath; John D Shannon; Suseela Sirinivasan; Mark R Conaway; Michael J Weber; Martin A Schwartz
Journal:  Pigment Cell Melanoma Res       Date:  2014-11-03       Impact factor: 4.693

7.  In vivo molecular imaging of myocardial angiogenesis using the alpha(v)beta3 integrin-targeted tracer 99mTc-RAFT-RGD.

Authors:  Julien Dimastromatteo; Laurent M Riou; Mitra Ahmadi; Guillaume Pons; Eric Pellegrini; Alexis Broisat; Lucie Sancey; Tatiana Gavrilina; Didier Boturyn; Pascal Dumy; Daniel Fagret; Catherine Ghezzi
Journal:  J Nucl Cardiol       Date:  2010-01-20       Impact factor: 5.952

8.  Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.

Authors:  Yoganand Balagurunathan; David L Morse; Galen Hostetter; Vijayalakshmi Shanmugam; Phillip Stafford; Sonsoles Shack; John Pearson; Maria Trissal; Michael J Demeure; Daniel D Von Hoff; Victor J Hruby; Robert J Gillies; Haiyong Han
Journal:  Mol Cancer Ther       Date:  2008-09-02       Impact factor: 6.261

9.  Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.

Authors:  Eric A Murphy; Bharat K Majeti; Leo A Barnes; Milan Makale; Sara M Weis; Kimberly Lutu-Fuga; Wolfgang Wrasidlo; David A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

Review 10.  Receptor-targeted nanocarriers for therapeutic delivery to cancer.

Authors:  Bo Yu; Heng Chiat Tai; Weiming Xue; L James Lee; Robert J Lee
Journal:  Mol Membr Biol       Date:  2010-10       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.